Glaxo unveils the next wave of medicines
GlaxoSmithKline expects to have pivotal clinical trial results on up to 14 medicines in the next two years, including two new products which – if they work – could change the way cancer and heart disease are treated.
Unveiling the next wave of its pipeline yesterday, Britain’s biggest drugmaker said it was now developing a broader range of drugs than in the past, as it moves away from the industry’s traditional focus on ‘blockbusters’.
Some of the new medicines will be relatively small commercially but a handful have the potential to become multi-billion-dollar-a-year sellers.
GSK is banking on the pipeline to revive its business after it failed to grow sales this year as previously hoped, due to steep pressure on drug prices in austerity-hit Europe.